• Leon F Palomera, Angélica Y Gómez-Arauz, Eréndira Villanueva-Ortega, Guillermo Meléndez-Mier, Sergio A Islas-Andrade, and Galileo Escobedo.
• Research Division, Laboratory for Proteomics and Metabolomics, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
• J Res Med Sci. 2018 Jan 1; 23: 93.

BackgroundIn high-fat diet-fed mice, interleukin-1 beta (IL-1 beta) has been shown to play a key role in hepatic steatosis. However, it remains unknown whether IL-1 beta could be associated with different grades of steatosis in obese humans.Materials And MethodsMorbidly obese patients (n = 124) aged 18-65 years were divided into four groups: no steatosis (controls), mild steatosis, moderate steatosis, and severe steatosis using abdominal ultrasound. IL-1 beta serum levels and liver function tests were measured and significant differences were estimated by one-way ANOVA followed by Tukey test.ResultsIL-1 beta serum levels significantly increased in morbidly obese patients with mild (11.38 ± 2.40 pg/ml), moderate (16.72 ± 2.47 pg/ml), and severe steatosis (23.29 ± 5.2 pg/ml) as compared to controls (7.78 ± 2.26 pg/ml). Liver function tests did not significantly change among different grades of steatosis.ConclusionIL-1 beta serum levels associate better with steatosis degree than liver function tests in morbidly obese population.

4 keywords...

hide…